Published in Br J Cancer on July 01, 2000
Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer (2005) 1.39
In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer (2006) 1.21
Cloning and characterization of osteoclast precursors from the RAW264.7 cell line. In Vitro Cell Dev Biol Anim (2006) 1.05
microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. Oncol Rep (2011) 0.95
Progress in the application of DNA microarrays. Environ Health Perspect (2001) 0.90
The influence of the Cyclin D1 870 G>A polymorphism as an endometrial cancer risk factor. BMC Cancer (2008) 0.85
Genomic-Wide Analysis with Microarrays in Human Oncology. Microarrays (Basel) (2015) 0.75
TIMP-3 and Phosphatidylinositol 3-kinase genes were found to be related to the progression of colon cancer in a comparison of pneumoperitoneum and laparotomy in a murine model. Surg Today (2007) 0.75
CDK-independent activation of estrogen receptor by cyclin D1. Cell (1997) 3.85
Endometrial carcinoma. N Engl J Med (1996) 3.31
GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer (1999) 2.77
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst (1999) 2.58
Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice. Mol Cell Biol (1999) 1.69
Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene (1999) 1.47
Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene (1992) 1.40
Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci U S A (1999) 1.39
Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res (1999) 1.31
Characterization of an early growth response gene, which encodes a zinc finger transcription factor, potentially involved in cell cycle regulation. Mol Endocrinol (1995) 1.22
International Federation of Gynecology and Obstetrics staging of endometrial cancer 1988. Cancer (1993) 1.17
Profiling of differentially expressed genes in human primary cervical cancer by complementary DNA expression array. Clin Cancer Res (1998) 1.15
Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res (1997) 1.11
cDNA expression array reveals heterogeneous gene expression profiles in three glioblastoma cell lines. Oncogene (1999) 0.99
Matrix metalloproteinases and their inhibitors. Anticancer Res (1999) 0.96
All in the (cancer) family. Nat Genet (1993) 0.93
Regulation of expression of Na+,K+-ATPase in androgen-dependent and androgen-independent prostate cancer. Br J Cancer (1999) 0.90
Epidemiology of endometrial neoplasia. J Cell Biochem Suppl (1995) 0.87
Advanced and recurrent endometrial carcinoma: hormonal therapy. Semin Oncol (1994) 0.81
Fra-1: a novel target for retinoid action. FEBS Lett (1999) 0.79
A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol (1997) 6.09
Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet (1999) 4.24
A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun (1990) 3.79
The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer (1995) 3.29
Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol (1991) 2.54
A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab (1998) 2.45
The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol (1992) 2.21
PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer (1996) 2.13
Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem (1996) 2.05
Tubal damage after intratubal methotrexate treatment. Fertil Steril (1993) 2.03
Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem (1995) 2.02
Current cup designs for obstetric vacuum extraction. Br J Obstet Gynaecol (1992) 2.00
Targeted disruption of the Insl3 gene causes bilateral cryptorchidism. Mol Endocrinol (1999) 1.99
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells. J Natl Cancer Inst (2000) 1.78
The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol (1991) 1.72
Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol (1999) 1.68
Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. J Clin Endocrinol Metab (1999) 1.67
Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum Genet (1997) 1.66
Prolapse of the sigmoid neovagina: report of three cases. Obstet Gynecol (1994) 1.66
Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Commun (1988) 1.64
Nuclear import of the human androgen receptor. Biochem J (1993) 1.58
Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet (2001) 1.56
A non-radioactive PCR enzyme-immunoassay enables a rapid identification of HPV 16 and 18 in cervical scrapes after GP5+/6+ PCR. J Med Virol (1996) 1.47
Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry (1992) 1.44
The low transverse Pfannenstiel incision and the prevalence of incisional hernia and nerve entrapment. Ann Surg (1997) 1.40
[High vacuum extraction: justifiably obsolete in view of the risks to the infant]. Ned Tijdschr Geneeskd (2001) 1.40
[Hendrik van Deventer:'father of modern obstetrics']. Ned Tijdschr Geneeskd (1986) 1.38
The N-terminal domain of the human androgen receptor is encoded by one, large exon. Mol Cell Endocrinol (1989) 1.38
Trinucleotide repeat polymorphism in the androgen receptor gene (AR). Nucleic Acids Res (1992) 1.34
Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol Endocrinol (1998) 1.26
Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy. Biochim Biophys Acta (1991) 1.24
Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry (1997) 1.24
Human papillomavirus in false negative archival cervical smears: implications for screening for cervical cancer. J Clin Pathol (1995) 1.21
Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol (1992) 1.18
17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations. J Clin Endocrinol Metab (1999) 1.16
Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer (2001) 1.15
A modified technique to create a neovagina with an isolated segment of sigmoid colon. Surg Gynecol Obstet (1992) 1.14
Characterization of an expanded glutamine repeat androgen receptor in a neuronal cell culture system. Neurobiol Dis (1997) 1.13
Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res (1997) 1.11
Aberrant splicing of androgen receptor mRNA results in synthesis of a nonfunctional receptor protein in a patient with androgen insensitivity. Proc Natl Acad Sci U S A (1990) 1.10
High-affinity binding of oestradiol-17beta by cytosols from testis interstitial tissue, pituitary, adrenal, liver and accessory sex glands of the male rat. Biochem J (1974) 1.09
Involvement of insulin-like factor 3 (Insl3) in diethylstilbestrol-induced cryptorchidism. Endocrinology (2000) 1.09
Steroid hormone receptor phosphorylation: is there a physiological role? Mol Cell Endocrinol (1994) 1.08
Domains of the human androgen receptor and glucocorticoid receptor involved in binding to the nuclear matrix. J Cell Biochem (1995) 1.07
A quantitative polymerase chain reaction-enzyme immunoassay for accurate measurements of human papillomavirus type 16 DNA levels in cervical scrapings. Br J Cancer (1999) 1.07
HPV typing and testing in gynaecological pathology: has the time come? Histopathology (1998) 1.06
The androgen receptor in prostate cancer. Pathol Res Pract (1996) 1.06
HPV 16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int J Cancer (1998) 1.06
An exonic point mutation of the androgen receptor gene in a family with complete androgen insensitivity. Am J Hum Genet (1990) 1.06
Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br J Cancer (2004) 1.06
Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature. Obstet Gynecol Surv (1998) 1.04
Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res (1998) 1.04
Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer (1994) 1.03
Characterization of the human androgen receptor transcription unit. J Biol Chem (1991) 1.03
Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. J Biol Chem (1993) 1.03
Detailed functional studies on androgen receptor mild mutations demonstrate their association with male infertility. Clin Endocrinol (Oxf) (2007) 1.02
High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. BJOG (2000) 0.99
Differential hormone-dependent transcriptional activation and -repression by naturally occurring human glucocorticoid receptor variants. Mol Endocrinol (1997) 0.98
Observer agreement on interpreting colposcopic images of CIN. Gynecol Oncol (1995) 0.98
Hormone-dependent androgen receptor phosphorylation is accompanied by receptor transformation in human lymph node carcinoma of the prostate cells. J Biol Chem (1991) 0.98
Functional domains of the human androgen receptor. J Steroid Biochem Mol Biol (1992) 0.97
Changes in the abundance of androgen receptor isotypes: effects of ligand treatment, glutamine-stretch variation, and mutation of putative phosphorylation sites. Biochemistry (1994) 0.97
Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but differ in their growth-stimulating properties of LNCaP cells. Endocrinology (1997) 0.97
Structure and function of GC79/TRPS1, a novel androgen-repressible apoptosis gene. Apoptosis (2002) 0.96
Phosphotryptic peptide analysis of the human androgen receptor: detection of a hormone-induced phosphopeptide. Biochemistry (1995) 0.95
Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol (2000) 0.94
Androgen receptor phosphorylation. Endocr Res (1996) 0.94
Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Pathol (1990) 0.93
Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer. Gynecol Oncol (1994) 0.93
Structural organization of the human androgen receptor gene. J Mol Endocrinol (1989) 0.93
Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst (1997) 0.93
Immunohistochemical detection of the androgen receptor with monoclonal antibody F39.4 in routinely processed, paraffin-embedded human tissues after microwave pre-treatment. J Histochem Cytochem (1994) 0.93
Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. Hum Mol Genet (1993) 0.93
Molecular analysis of the androgen-receptor gene in a family with receptor-positive partial androgen insensitivity: an unusual type of intronic mutation. Am J Hum Genet (1997) 0.93
The mouse androgen receptor. Functional analysis of the protein and characterization of the gene. Biochem J (1991) 0.93
Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. J Clin Endocrinol Metab (1995) 0.92
Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. Endocrinology (1995) 0.92
Intraperitoneal photodynamic therapy in the rat: comparison of toxicity profiles for photofrin and MTHPC. Int J Cancer (1994) 0.92
Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells. Cancer Res (2001) 0.91
Forskolin-induced dephosphorylation of the androgen receptor impairs ligand binding. Biochemistry (1998) 0.91
Hormonal control of gubernaculum development during testis descent: gubernaculum outgrowth in vitro requires both insulin-like factor and androgen. Endocrinology (2000) 0.91
Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study. Endocr Relat Cancer (2005) 0.91
HPV DNA presence and HPV genotypes as prognostic factors in low-stage squamous cell cervical cancer. Gynecol Oncol (1993) 0.91
Differential splicing of human androgen receptor pre-mRNA in X-linked Reifenstein syndrome, because of a deletion involving a putative branch site. Am J Hum Genet (1994) 0.91
Regulation of expression of Na+,K+-ATPase in androgen-dependent and androgen-independent prostate cancer. Br J Cancer (1999) 0.90
Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients. Cancer Res (1993) 0.90
Complications of anticoagulant therapy in ovulatory women. Lancet (1991) 0.90
A randomized comparison of vacuum extraction delivery with a rigid and a pliable cup. Obstet Gynecol (1993) 0.89
Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Cancer (1995) 0.88
An oestradiol receptor in rat testis interstitial tissue. FEBS Lett (1972) 0.88
Synthesis and post-translational modification of the androgen receptor in LNCaP cells. Mol Cell Endocrinol (1991) 0.88
Mosaicism due to a somatic mutation of the androgen receptor gene determines phenotype in androgen insensitivity syndrome. J Clin Endocrinol Metab (1997) 0.87
Localization and hormonal stimulation of phosphorylation sites in the LNCaP-cell androgen receptor. Biochem J (1993) 0.87